Opioid Analgesics Market by Segmentation type— Global Forecast to 2032

According to a comprehensive study conducted by FMI, the Global Opioid Analgesics Market is expected to reach US$ 65.8 billion by 2031. In response to rising demand for post-surgery pain management and a focus on novel drug formulations for analgesics, the market is expected to grow at a CAGR of 5.4% from 2021 to 2031, compared to a CAGR of 4.2% from 2016 to 2020.

The growing prevalence of chronic disorders, neuropathic pain, and orthopaedic diseases is driving the opioid analgesics market. Opioids are widely used for anaesthesia, cough suppression, cancer pain management, and the treatment of a variety of other ailments. Furthermore, the development of novel analgesics with fewer side effects is expected to increase sales by 1.7X by 2031.

In recent years, there has been a significant increase in the number of surgical procedures performed. In 2019, approximately 11.3 million surgeries were reported worldwide, according to the International Society of Aesthetic Plastic Surgery (ISAPS). Because opioids are used to manage and reduce pain after surgery, the surgical pain indication segment is expected to account for nearly 45.9% of total sales by 2031.

Get a Sample PDF Report@
https://www.futuremarketinsights.com/reports/sample/rep-gb-14043

The growth in the region is attributed to the increasing prevalence of chronic diseases and presence of favorable medical reimbursement policies in the U.K and Germany.

“Commercialization of non-abusive opioids and increasing availability of opioid analgesics through online distribution channels are expected to accelerate the sales of opioid analgesics,” says the FMI analyst.

Key Takeaways from Opioid Analgesics Market Study

• The U.S. is anticipated to lead the market in North America, accounting for nearly 86% of the overall sales in 2021.
• Sales of opioid analgesics in Germany are estimated to total US$ 2.2 billion, growing at a CAGR of 3.8% during the assessment period.
• The market in India is forecast to account for 35.4% of the sales in South Asia, expanding at a CAGR of 5.7% between 2021 and 2031.
• China is expected to emerge as the most lucrative market for opioid analgesics in East Asia, contributing around 54.2% of the sales revenue in the region by 2021 end.
• Among drug class verticals, oxycodone is estimated to dominate the segment accounting for more than 19% of the global demand in 2021.

Key Drivers

• Surging demand for facial and body aesthetics in response to the rising number of aesthetic surgical procedures such as breast implantation, eyelid surgeries, and abdominoplasty conducted worldwide will spur the sales across surgical pain segment.
• Increasing adoption of opioid maintenance treatment (OMT) for treating opioid dependence (OD) across Germany, the U.K., the U.S., and others are anticipated to drive the market growth.

Key Restraints

• Side effects associated with opioid analgesics such as drowsiness, nausea, constipation, clouded thinking, and psychological & physical addiction are hampering the market growth.
• Stringent government regulation and guidelines regarding manufacturing, storage, marketing, and selling of opioid products are restraining the growth of opioid analgesics.

Ask to Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-14043

Competitive Analysis

Leading manufacturers are emphasizing on launching new and revised products to enhance their product portfolios. Strategies such as product approvals, partnerships, agreements, merger, facility expansion, and collaborations are expected to assist market players strengthen their footprint and gain a competitive edge over other players. For instance,

In May 2020, Assertio Therapeutics, Inc., an American specialty pharmaceutical company, announced entering into merger agreement with a U.S.-based pharmaceutical company, Zyla Life Sciences. The merger will assist companies to expand their product portfolio of inflammation, neurology, and chronic pain medications.

In September 2018, Novartis, a Swiss multinational pharmaceutical corporation, announced signing an agreement for marketing, distribution, and sales, of well-known pain medicine brands such as Cataflam (diclofenac potassium) and Voltaren (diclofenac sodium) in Thailand, Malaysia and Philippines.

• Pfizer Inc.
• Abbott Laboratories
• Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
• Novartis AG
• Bayer AG
• GlaxoSmithKline plc
• F. Hoffmann-La Roche AG,
• Boehringer Ingelheim International GmbH
• Bausch Health Companies Inc.
• Sanofi S.A.
• Teva Pharmaceuticals
• AbbVie Inc. (Allergan plc)
• Purdue Pharmaceuticals L.P.
• Sun Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Endo Pharmaceuticals Inc. [Endo International plc]
• Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]

Opioid Analgesics Market by Category

By Drug Class:

• Morphine
• Codeine
• Fentanyl
• Meperidine
• Methadone
• Tramadol
• Oxycodone
• Dextromethorphan
• Buprenorphine
• Others

By Indication:

• Surgical Pain
• Cancer Pain
• Neuropathic Pain
• Other

By Route of Administration:

• Oral
• Parenteral
• Transdermal
• Other

By End User:

• Hospitals
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

Buy this Report Now@
https://www.futuremarketinsights.com/checkout/14043

Read Related Reports:

https://degentevakana.com/blogs/view/121254
https://vocal.media/stories/hypoparathyroidism-treatment-market-2022-scope-of-current-and-future-industry-2031
https://www.dronepilotlari.com/blogs/52528/Saudi-Arabia-Pharmaceutical-Market-2022-Key-Players-SWOT-Analysis-Key
https://vocal.media/stories/frontotemporal-disorders-treatment-market-2022-scope-of-current-and-future-industry-2028

About FMI                     

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:                                        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Report: https://www.futuremarketinsights.com/reports/opioid-analgesics-market
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs